She/Her/Hers
Job Title
Instructor
Academic Rank
Instructor
Department
Radiation Oncology
Authors
Sayeda Yasmin-Karim, Amanda Fam, Geraud Richard, Mike Makrigiorgos
Principal Investigator
Mike Makrigiorgos
Categories
Tags
Purpose: Radiation induces apoptosis, causing cancer cells to be fragmented and expose the cancer-associated antigens to the tumor microenvironment. These can be recognized by antigen-recenting cells (APC) to induce the antineoplastic effect by activating cytotoxic T cells. Flavonoids like Hesperetin, an ACE2 receptor, agonist also can induce apoptosis in cancer cells whereas ACE2 receptors are abundant in lung cancer cells.
This project aims to develop a novel treatment for non-small cell lung cancer (NSCLC) using nanotechnology for inhalation drug delivery of Hesperetin nanoparticles (HNP) with immunotherapy.
Methods: We developed syngeneic orthotopic murine lung tumors with luciferase gene transfected LL/2-Luc2 (ATCC) Lung Cancer cell line in C57BL/6 mice (Taconic). We prepared HNP for the aerosol drug delivery.
Results: We were able to successfully develop an aerosol drug delivery model to administer both Anti-CD40 and HNP in murine cancer lungs. In our analysis in an orthotopic murine lung cancer model, we demonstrate a higher percent survival rate with combination aerosol treatment with HNP+AntiCD40 (p<0.001), compared to CD40 alone (p<0.01) or HNP alone.
Comments: This treatment model will allow us to make the lung cancer treatment method easily available for the mass population without having hazardous radiation treatment in the lung cancer model.
Purpose: Radiation induces cell death, causing cancer cells to be fragmented and expose to the immune system. These can be recognized by macrophages to induce the anticancer effect by activating the anticancer immune system. Flavonoids like Hesperetin, an ACE2 receptor, agonist also can induce cell death in cancer cells whereas ACE2 receptors are abundant in lung cancer cells.
This project aims to develop a novel treatment for non-small cell lung cancer (NSCLC) using nanotechnology for inhalation drug delivery of Hesperetin nanoparticles (HNP) with immunotherapy.
Methods: We developed immune-competent mouse lung tumors with Lung Cancer cell line in C57BL/6 mice (Taconic). We prepared HNP for the aerosol drug delivery.
Results: We were able to successfully develop an aerosol drug delivery model to administer both Anti-CD40 and HNP in murine cancer lungs. In our analysis of an orthotopic murine lung cancer model, we demonstrate a higher percent survival rate with combination aerosol treatment with HNP+AntiCD40 (p<0.001), compared to CD40 alone (p<0.01) or HNP alone.
Comments: This treatment model will allow us to make the lung cancer treatment method easily available for the mass population without having hazardous radiation treatment in the lung cancer model.
